The complex roles of Wnt antagonists in RCC

Sharanjot Saini, Shahana Majid, Rajvir Dahiya

Research output: Contribution to journalReview article

Abstract

Renal cell carcinoma (RCC) is the most lethal of all the genitourinary cancers, as it is generally refractory to current treatment regimens, including chemotherapy and radiation therapy. Targeted therapies against critical signaling pathways associated with RCC pathogenesis, such as vascular endothelial growth factor, von Hippel - Lindau tumor suppressor and mammalian target of rapamycin, have shown limited efficacy so far. Thus, Wnt signaling, which is known to be intricately involved in the pathogenesis of RCC, has attracted much interest. Several Wnt signaling components have been examined in RCC, and, while studies suggest that Wnt signaling is constitutively active in RCC, the molecular mechanisms differ considerably from other human carcinomas. Increasing evidence indicates that secreted Wnt antagonists have important roles in RCC pathogenesis. Considering these vital roles, it has been postulated - and supported by experimental evidence - that the functional loss of Wnt antagonists, for example by promoter hypermethylation, can contribute to constitutive activation of the Wnt pathway, resulting in carcinogenesis through dysregulation of cell proliferation and differentiation. However, subsequent functional studies of these Wnt antagonists have demonstrated the inherent complexities underlying their role in RCC pathogenesis.

Original languageEnglish (US)
Pages (from-to)690-699
Number of pages10
JournalNature Reviews Urology
Volume8
Issue number12
DOIs
StatePublished - Dec 1 2011
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Urogenital Neoplasms
Wnt Signaling Pathway
Critical Pathways
Sirolimus
Vascular Endothelial Growth Factor A
Cell Differentiation
Carcinogenesis
Radiotherapy
Cell Proliferation
Carcinoma
Drug Therapy
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

The complex roles of Wnt antagonists in RCC. / Saini, Sharanjot; Majid, Shahana; Dahiya, Rajvir.

In: Nature Reviews Urology, Vol. 8, No. 12, 01.12.2011, p. 690-699.

Research output: Contribution to journalReview article

Saini, S, Majid, S & Dahiya, R 2011, 'The complex roles of Wnt antagonists in RCC', Nature Reviews Urology, vol. 8, no. 12, pp. 690-699. https://doi.org/10.1038/nrurol.2011.146
Saini, Sharanjot ; Majid, Shahana ; Dahiya, Rajvir. / The complex roles of Wnt antagonists in RCC. In: Nature Reviews Urology. 2011 ; Vol. 8, No. 12. pp. 690-699.
@article{101680ae6e2e402b98bdf4d37d86c33a,
title = "The complex roles of Wnt antagonists in RCC",
abstract = "Renal cell carcinoma (RCC) is the most lethal of all the genitourinary cancers, as it is generally refractory to current treatment regimens, including chemotherapy and radiation therapy. Targeted therapies against critical signaling pathways associated with RCC pathogenesis, such as vascular endothelial growth factor, von Hippel - Lindau tumor suppressor and mammalian target of rapamycin, have shown limited efficacy so far. Thus, Wnt signaling, which is known to be intricately involved in the pathogenesis of RCC, has attracted much interest. Several Wnt signaling components have been examined in RCC, and, while studies suggest that Wnt signaling is constitutively active in RCC, the molecular mechanisms differ considerably from other human carcinomas. Increasing evidence indicates that secreted Wnt antagonists have important roles in RCC pathogenesis. Considering these vital roles, it has been postulated - and supported by experimental evidence - that the functional loss of Wnt antagonists, for example by promoter hypermethylation, can contribute to constitutive activation of the Wnt pathway, resulting in carcinogenesis through dysregulation of cell proliferation and differentiation. However, subsequent functional studies of these Wnt antagonists have demonstrated the inherent complexities underlying their role in RCC pathogenesis.",
author = "Sharanjot Saini and Shahana Majid and Rajvir Dahiya",
year = "2011",
month = "12",
day = "1",
doi = "10.1038/nrurol.2011.146",
language = "English (US)",
volume = "8",
pages = "690--699",
journal = "Nature Reviews Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - The complex roles of Wnt antagonists in RCC

AU - Saini, Sharanjot

AU - Majid, Shahana

AU - Dahiya, Rajvir

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Renal cell carcinoma (RCC) is the most lethal of all the genitourinary cancers, as it is generally refractory to current treatment regimens, including chemotherapy and radiation therapy. Targeted therapies against critical signaling pathways associated with RCC pathogenesis, such as vascular endothelial growth factor, von Hippel - Lindau tumor suppressor and mammalian target of rapamycin, have shown limited efficacy so far. Thus, Wnt signaling, which is known to be intricately involved in the pathogenesis of RCC, has attracted much interest. Several Wnt signaling components have been examined in RCC, and, while studies suggest that Wnt signaling is constitutively active in RCC, the molecular mechanisms differ considerably from other human carcinomas. Increasing evidence indicates that secreted Wnt antagonists have important roles in RCC pathogenesis. Considering these vital roles, it has been postulated - and supported by experimental evidence - that the functional loss of Wnt antagonists, for example by promoter hypermethylation, can contribute to constitutive activation of the Wnt pathway, resulting in carcinogenesis through dysregulation of cell proliferation and differentiation. However, subsequent functional studies of these Wnt antagonists have demonstrated the inherent complexities underlying their role in RCC pathogenesis.

AB - Renal cell carcinoma (RCC) is the most lethal of all the genitourinary cancers, as it is generally refractory to current treatment regimens, including chemotherapy and radiation therapy. Targeted therapies against critical signaling pathways associated with RCC pathogenesis, such as vascular endothelial growth factor, von Hippel - Lindau tumor suppressor and mammalian target of rapamycin, have shown limited efficacy so far. Thus, Wnt signaling, which is known to be intricately involved in the pathogenesis of RCC, has attracted much interest. Several Wnt signaling components have been examined in RCC, and, while studies suggest that Wnt signaling is constitutively active in RCC, the molecular mechanisms differ considerably from other human carcinomas. Increasing evidence indicates that secreted Wnt antagonists have important roles in RCC pathogenesis. Considering these vital roles, it has been postulated - and supported by experimental evidence - that the functional loss of Wnt antagonists, for example by promoter hypermethylation, can contribute to constitutive activation of the Wnt pathway, resulting in carcinogenesis through dysregulation of cell proliferation and differentiation. However, subsequent functional studies of these Wnt antagonists have demonstrated the inherent complexities underlying their role in RCC pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=83555173400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83555173400&partnerID=8YFLogxK

U2 - 10.1038/nrurol.2011.146

DO - 10.1038/nrurol.2011.146

M3 - Review article

C2 - 22025172

AN - SCOPUS:83555173400

VL - 8

SP - 690

EP - 699

JO - Nature Reviews Urology

JF - Nature Reviews Urology

SN - 1759-4812

IS - 12

ER -